It's crystal clear how you are trying to downramp this stock for a lower reentry. I suggest you offer something meaningful in the way of figures or valuations or just stop downramping.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025